1 |
Spitz MR, Hong WK, Amos CI, Wu X, Schabath MB, Dong Q, et al. A risk model for prediction of lung cancer. J Natl Cancer Inst 2007; 99(9): 715-726
DOI
ScienceOn
|
2 |
Optenberg SA, Clark JY, Brawer MK, Thompson IM, Stein CR, Friedrichs P. Development of a decision-making tool to predict risk of prostate cancer: The Cancer of the Prostate Risk Index (CAPRI) test. Urology 1997; 50(5): 665-672
DOI
ScienceOn
|
3 |
Wang W, Chen S, Brune KA, Hruban RH, Parmigiani G, Klein AP. PancPRO: Risk
assessment for individuals with a family history of pancreatic cancer. J Clin Oncol 2007; 25(11): 1417-1422
DOI
ScienceOn
|
4 |
Wu X, Gu J, Spitz MR. Strategies to identify pharmacogenomic biomarkers: Candidate gene, pathway-based, and genome-wide approaches. In: Innocenti F, editor. Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response. New Jersey: Humana Press; 2009. p. 353-370
|
5 |
Quintela-Fandino M, Hitt R, Medina PP, Gamarra S, Manso L, Cortes-Funes H, et al. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. J Clin Oncol 2006; 24(26): 4333-339
DOI
ScienceOn
|
6 |
Ulrich CM, Ambrosone CB. Molecular epidemiology designs for prognosis. In:Rebbeck TR, Ambrosone CB, Shields PG, editors. Molecular Epidemiology: Applications in Cancer and Other Human Diseases. New York: Informa Heathcare; 2008: p. 41-52
|
7 |
Imperiale TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, Ransohoff DF. Using risk for advanced proximal colonic neoplasia to tailor endoscopic screening for colorectal cancer. Ann Intern Med 2003; 139(12): 959-965
DOI
PUBMED
ScienceOn
|
8 |
Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. InJ Natl Cancer st 2006; 98(17): 1183-1192
DOI
PUBMED
ScienceOn
|
9 |
Hirschhorn JN. Genomewide association studies: Illuminating biologic pathways. N Engl J Med 2009; 360(17): 1699-1701
DOI
ScienceOn
|
10 |
Kannel WB, McGee D, Gordon T. A general cardiovascular risk profile: The Framingham Study. Am J Cardiol 1976; 38(1): 46-51
DOI
ScienceOn
|
11 |
Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): A randomised prevention trial. Lancet 2002; 360(9336): 817-824
DOI
PUBMED
ScienceOn
|
12 |
Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine Smethyltransferase gene locus. J Natl Cancer Inst 1999; 91(23): 2001-2008
DOI
PUBMED
|
13 |
Berry DA, Parmigiani G, Sanchez J, Schildkraut J, Winer E. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst 1997; 89(3): 227-238
DOI
ScienceOn
|
14 |
Meyer UA. Pharmacogenetic: five decades of therapeutic lessons from genetic diversity. Nat Rev Genet 2004; 5(9): 669-676
DOI
PUBMED
ScienceOn
|
15 |
Ziegler A, Konig IR, Thompson JR. Biostatistical aspects of genome-wide
association studies. Biom J 2008; 50(1): 8-28
DOI
ScienceOn
|
16 |
Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360(8): 753-764
DOI
ScienceOn
|
17 |
Nasir K, Michos ED, Blumenthal RS, Raggi P. Detection of high-risk young adults and women by coronary calcium and National Cholesterol Education Program Panel III guidelines. J Am Coll Cardiol 2005; 46(10): 1931-1936
DOI
ScienceOn
|
18 |
Wu X, GU J. Pharmacogenetics in cancer chemotherapy. In: Rebbeck TR, Ambrosone CB, Shields PG, editors. Molecular Epidemiology: Applications in Cancer and Other Human Diseases. New York: Informa Heathcare; 2008. p.113-128
|
19 |
Colditz GA, Atwood KA, Emmons K, Monson RR, Willett WC, Trichopoulos D, et al. Harvard report on cancer prevention volume 4. Harvard Cancer Risk Index: Risk Index Working Group, Harvard Center for Cancer Prevention. Cancer Causes Control 2000; 11(6): 477-488
DOI
ScienceOn
|
20 |
Beane J, Sebastiani P, Whitfield TH, Steiling K, Dumas YM, Lenburg ME, et al. A prediction model for lung cancer diagnosis that integrates genomic and clinical features. Cancer Prev Res (Phila Pa) 2008; 1(1): 56-64
DOI
ScienceOn
|
21 |
National Heart Lung and Blood Institute. Risk Assessment Tool for Estimating Your 10-year Risk of Having a Heart Attack. Bethesda, MD: National Heart Lung and Blood Institute; 2004 [cited 2009 Oct 10]. Available from: URL:http://hp2010.nhlbihin.net/ATPiii/calcula tor.asp
|
22 |
National Cancer Institute. Breast cancer risk assessment tool. Bethesda, MD: National Cancer Institute; 2007 [cited 2009 Oct 5]. Available from: URL:http://www.cancer. gov/bcrisktool/
|
23 |
Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ramirez J, Relling M, et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 2009; 27(16): 2604-2614
DOI
ScienceOn
|
24 |
Wang WY, Barratt BJ, Clayton DG, Todd JA. Genome-wide association studies: Theoretical and practical concerns. Nat Rev Genet 2005; 6(2): 109-118
DOI
ScienceOn
|
25 |
Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97(18): 1837-1847
DOI
PUBMED
ScienceOn
|
26 |
Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting
individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81(24): 1879-1886
DOI
PUBMED
|
27 |
Fears TR, Guerry D 4th, Pfeiffer RM, Sagebiel RW, Elder DE, Halpern A, et al. Identifying individuals at high risk of melanoma: A practical predictor of absolute risk. J Clin Oncol 2006; 24(22): 3590-3596
DOI
ScienceOn
|
28 |
Food and Drug Administration, HHS. International Conference on Harmonisation; Guidance on E15 pharmacogenomics Definitions and Sample Coding; Availability. notice. Fed Regist 2008; 73(68): 19074-19076
|
29 |
Food and Drug Administration. Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels. Silver Spring, MD: Food and Drug Administration; 2009 [cited 2009 Oct 5]. Available from: URL:http://www.fda.gov/Drugs/ScienceResearch/Researc hAreas/Pharmacogenetics/ucm083378.htm
|
30 |
Johnson KM, Dowe DA, Brink JA. Traditional clinical risk assessment tools do not accurately predict coronary atherosclerotic plaque burden: A CT angiography study. AJR Am J Roentgenol 2009; 192(1): 235-243
DOI
ScienceOn
|
31 |
Bellcross CA, Lemke AA, Pape LS, Tess AL, Meisner LT. Evaluation of a breast/ovarian cancer genetics referral screening tool in a mammography population. Genet Med 2009. Epub 2009 Sep 11
DOI
PUBMED
ScienceOn
|
32 |
Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer: Implications for risk prediction. Cancer 1994; 73(3): 643-651
DOI
ScienceOn
|
33 |
Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, et al. SLCO1B1 variants and statin-induced myopathy: A genomewide study. N Engl J Med 2008; 359(8): 789-799
DOI
ScienceOn
|
34 |
Bach PB, Kattan MW, Thornquist MD, Kris MG, Tate RC, Barnett MJ, et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst 2003; 95(6): 470-478
DOI
PUBMED
ScienceOn
|
35 |
Akosah KO, Schaper A, Cogbill C, Schoenfeld P. Preventing myocardial infarction in the young adult in the first place: How do the National Cholesterol Education Panel III guidelines perform? J Am Coll Cardiol 2003; 41(9): 1475-1479
DOI
ScienceOn
|
36 |
Selvachandran SN, Hodder RJ, Ballal MS, Jones P, Cade D. Prediction of colorectal cancer by a patient consultation questionnaire and scoring system: A prospective study. Lancet 2002; 360(9329): 278-283
DOI
ScienceOn
|
37 |
Demchuk E, Yucesoy B, Johnson VJ, Andrew M, Weston A, Germolec DR, et al. A statistical model for assessing genetic susceptibility as a risk factor in multifactorial diseases: Lessons from occupational asthma. Environ Health Perspect 2007; 115(2): 231-234
PUBMED
|
38 |
Gail MH. Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. J Natl Cancer Inst 2008; 100(14): 1037-1041
DOI
ScienceOn
|
39 |
Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360(4): 363-375
DOI
ScienceOn
|
40 |
Center for Drug Evaluation Research, Center for Biologic Evaluation Research, Center for Devices and Radiological Health. Guidance for Industry Pharmacogenomic Data Submissions. Silver Spring, MD: Food and Drug Administration; 2005 [cited 2009 Oct 5]. Available from: URL: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm126957.pdf
|
41 |
Roses AD. Pharmacogenetics in drug discovery and development: A translational perspective. Nat Rev Drug Discov 2008; 7(10): 807-817
DOI
PUBMED
ScienceOn
|
42 |
McCanlies E, Landsittel DP, Yucesoy B, Vallyathan V, Luster ML, Sharp DS. Significance of genetic information in risk assessment and individual classification using silicosis as a case model. Ann Occup Hyg 2002; 46(4): 375-381
DOI
ScienceOn
|
43 |
National Human Genome Research Institute. A Catalog of Published Genome-Wide Association Studies. Bethesda, MD: National Human Genome Research Institute; 2009 [cited 2009 Oct 5]. Available from: URL: http://www.genome.gov/26525384
|
44 |
Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: Theoretical considerations and practical challenges. J Clin Oncol 2009; 27(24): 4027-4034
DOI
ScienceOn
|
45 |
Schulte PA, Waters M. Using molecular epidemiology in assessing exposure for risk assessment. Ann N Y Acad Sci 1999; 895: 101-111
DOI
PUBMED
|
46 |
Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, et al. Medical genetics: A marker for Stevens-Johnson syndrome. Nature 2004; 428(6982): 486
DOI
ScienceOn
|
47 |
Sparano JA, Paik S. Development of the 21- gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008;26(5): 721-728
DOI
ScienceOn
|
48 |
Gail MH. Value of adding single-nucleotide polymorphism genotypes to a breast cancer risk model. J Natl Cancer Inst 2009; 101(13): 959-963
DOI
ScienceOn
|